AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01443442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol etabonate
Description: Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days
Study NCT03339518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRIM3 educational intervention
Description: Breast Cancer risk education and counseling
Study NCT03339518 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait List
Description: Booklet at the end of study
Study NCT00732121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg daily for 4 weeks
Study NCT00732121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02799745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Oral
Study NCT03176732 — intervention group
Intervention type: DEVICE
Intervention: Positive Airway Pressure
Description: Participants will use Positive Airway Pressure (PAP) treatment
Study NCT01507428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-Fluoromisonidazole
Description: Undergo FMISO PET/CT (Correlative studies)
Study NCT01507428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluoromisonidazole
Description: Undergo FMISO PET/CT (Correlative studies)
Study NCT01507428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT01507428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01507428 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo FDG PET/CT
Study NCT01507428 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG PET/CT
Study NCT01507428 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo FMISO PET/CT (Correlative studies)
Study NCT01507428 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FMISO PET/CT (Correlative studies)
Study NCT01507428 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo radiotherapy
Study NCT01507428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG PET/CT
Study NCT01507428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG PET/CT
Study NCT01507428 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-Guided Adaptive Radiation Therapy
Description: Undergo individualized adaptive radiotherapy
Study NCT01507428 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01507428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01507428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT01507428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01507428 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo FDG PET/CT
Study NCT01507428 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG PET/CT
Study NCT01507428 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo FMISO PET/CT (Correlative studies)
Study NCT01507428 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FMISO PET/CT (Correlative studies)
Study NCT00648297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg
Description: 80/5mg, single dose fed
Study NCT00648297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corzide® Tablets 80 mg/5 mg
Description: 80/5mg, single dose fed
Study NCT01435005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Volume
Description: Moderate volume (150 minutes per week) aerobic exercise
Study NCT01435005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Volume
Description: Participate in one-year high volume (300 minutes per week)aerobic exercise.
Study NCT02358889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hI-con1
Description: Intravitreal injection of hI-con1 0.3 mg
Study NCT02358889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Intravitreal injection of ranibizumab 0.5 mg
Study NCT02358889 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Intravitreal injection of ranibizumab 0.5 mg
Study NCT02358889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham injection
Description: No injection is given, a needleless syringe is used to mimic an injection.
Study NCT02358889 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham injection
Description: No injection is given, a needleless syringe is used to mimic an injection.
Study NCT03049163 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: vitrectomy under topical anesthesia [Proparacaine HCL (Alcaine®)]
Description: to observe the anesthesia effect of topical anesthesia of 27-gauge vitrectomy for vitreous floaters
Study NCT03049163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitrectomy under topical anesthesia [Proparacaine HCL (Alcaine®)]
Description: to observe the anesthesia effect of topical anesthesia of 27-gauge vitrectomy for vitreous floaters
Study NCT04046471 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: enhanced Stop Light Diet
Description: Stop light diet enhanced with portion-controlled meals
Study NCT04046471 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group Remote
Description: Participants will receive remotely delivered weight loss in a group setting.
Study NCT04046471 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Individual In-Person
Description: Participants will receive a weight loss intervention during individual, at-home visits.
Study NCT01850004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Study NCT02816216 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CampAir
Description: An empirically-based dynamic e-health intervention (based on the evidence-based ASMA) to assist adolescents with uncontrolled asthma to learn how to manage their illness and improve their asthma control.
Study NCT04160299 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance-based exergaming
Description: Dance sessions
Study NCT00999349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin (LEGALON)
Description: Study group: Silymarin Capsule, 140 mg, 3 times a day + desferrioxamine injection 50 mg/kg, Placebo group:Placebo capsules Similar to Silymarin +desferrioxamine injection 50 mg/kg
Study NCT03725436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDM2/MDMX Inhibitor ALRN-6924
Description: Given IV
Study NCT03725436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01262391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate suspension 2.5 mg
Description: Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 2.5 mg of solifenacin once daily in adults.
Study NCT01262391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate suspension 5 mg
Description: Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 5 mg dose of solifenacin once daily in adults.
Study NCT00999349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01245179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Panobinostat oral capsules taken THRICE WEEKLY (Monday, Wednesday, and Friday) for 12 weeks, exploring the following dosing regimens:~1. 15 mg MWF 3 weeks on, 1 week off (if needed)~2. 15 mg MWF every week (starting dose)~3. 20 mg MWF 3 weeks on, 1 week off~4. 20 mg MWF every week
Study NCT00428610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY573636-sodium
Description: LY573636 dose is dependent on participant's height, weight, and gender and is adjusted to target a specific maximum concentration (Cmax) based on participant laboratory parameters. LY573636 is administered every 28 days until disease progression or other criteria for participant discontinuation are met.
Study NCT00906646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Metabolic therapy
Description: Coenzyme Q10 - 100 mg tds Magnesium orotate - 400 mg tds Lipoic acid - 100 mg tds Omega-3 fatty acids - 300 mg (in 1 g fish oils) tds Selenium - 200 µg
Study NCT00906646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT01262391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate suspension 10 mg
Description: Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses 10 mg dose of solifenacin once daily in adults.
Study NCT02851238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving Pressure Limited Ventilation
Description: Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 2 to 10 cmH2O during one-lung ventilation
Study NCT02386202 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No interventions
Study NCT01831375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speak Up
Description: Intervention group_treatment group
Study NCT01831375 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Get connected
Description: Participants will learn to be connected with social resources in the community.
Study NCT01970202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40mg Enoxaparin
Description: Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 40mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
Study NCT01970202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 60mg Enoxaparin
Description: Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 60mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
Study NCT01970202 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: no treatment
Study NCT00466960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC
Study NCT00466960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV
Study NCT00466960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00466960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Description: Correlative studies
Study NCT04114058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal bupivicaine
Description: local field infiltration
Study NCT04114058 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia iliaca blockade
Description: fascia iliaca compartment blockade
Study NCT02995395 — intervention group
Intervention type: DEVICE
Intervention: Mucosal Impedance Balloon catheter
Description: During the clinical endoscopy (a standard procedure that allows your doctor to look at the inside of your swallowing tube), the 2 mm catheter (tiny tube), called an Intraluminal Impedance Balloon, will be passed through the channel of the standard endoscope.~o The catheter (tiny tube) will be placed through the endoscope in your esophagus (swallowing tube) for two minutes, readings from the catheter will be recorded.
Study NCT01947803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate
Description: Paliperidone Palmitate is injected with a dose of 150 mg eq. on Day 1 and 100 mg eq. on Day 8 in the deltoid muscle, followed by a monthly flexible dose range of 75 - 150 mg eq. for injection, based on patients' tolerability and/or efficacy. Monthly doses can be administered in either the deltoid or gluteal muscle alternatively. All the antipsychotics should be discontinued prior to the first dose of study drug. Other antipsychotics are prohibited across this study.
Study NCT04613297 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Baseline and during hospitalization blood samples
Description: Blood sample will be performed at the inclusion visit for all patient and for the hospitalized COVID-19 infected patients, extra-blood samples will be performed :~* at day 3~* day 5 and~* In case of aggravation~* At the discharge from hospital
Study NCT04613297 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Baseline blood sample
Description: Blood sample will be performed at the inclusion visit only
Study NCT01978405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alpha lipoic acid
Study NCT01978405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid
Study NCT03436472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: low-dose dexmedetomidine infusion
Study NCT03436472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline infusion
Study NCT02799745 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Active Surveillance
Study NCT03094143 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aortic valve intervention
Description: The choice of either surgical aortic valve replacement or transcatheter aortic valve implantation (TAVI) will be made by the local clinical team according to local policies. In patients undergoing surgical replacement the choice of surgical technique and type of valve replacement used will be at the discretion of the operating surgeon. Patients found to have significant coronary artery disease requiring concomitant coronary artery bypass surgery will not be excluded. Similarly the choice of TAVI valve and need for percutaneous coronary intervention will be made by the TAVI heart team. The procedure should be performed as soon as possible and ideally within four months of randomisation and allocation to group A.
Study NCT04688554 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI and DTI
Description: Neurologic imaging correlates
Study NCT03989102 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Sterile isotonic (0.9%) normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe; and will be used as a placebo, rather than a comparator vaccine
Study NCT01741038 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim®
Description: AlloStim® is derived from the blood of normal blood donors and is intentionally mismatched to the recipient. CD4+ T-cells are separated from the blood and differentiated and expanded for 9-days in culture to make an intermediary called T-Stim. AlloStim is made by incubating T-Stim cells for 4h with antibody coated microbeads. The cells with the beads still attached are suspended in infusion media and loaded into syringes. The syringes are shipped refrigerated to the point-of-care.
Study NCT01741038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryoablation
Description: percutaneous ablation of a single metastatic tumor lesion usually in liver. The procedure is conducted under CT or ultrasound image-guidance.
Study NCT01741038 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cryoablation
Description: percutaneous ablation of a single metastatic tumor lesion usually in liver. The procedure is conducted under CT or ultrasound image-guidance.
Study NCT01741038 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physician's Choice (PC)
Description: Physician's Choice therapy can consist of best supportive care (BSC) or any US-FDA approved cancer drug (e.g. Cetuximab) administrated as a monotherapy at the manufacturer's recommended dose. The treatment schedule shall be prospectively determined and administered as tolerated
Study NCT02570321 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal Cross-linking
Description: For those subjects randomized to receive collagen cross-linking, the procedure will be performed as per the routine at the hospital (UV-X machine; strict aseptic precautions; corneal epithelium debrided and 0.1% riboflavin applied for 30 minutes, then UV-A radiation applied for 30 minutes at 370nm with 3mW/cm2). Corneal cross-linking is a routine procedure performed by Aravind Eye Hospital for infectious keratitis.
Study NCT02570321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal Cross-linking
Description: For those subjects randomized to receive collagen cross-linking, the procedure will be performed as per the routine at the hospital (UV-X machine; strict aseptic precautions; corneal epithelium debrided and 0.1% riboflavin applied for 30 minutes, then UV-A radiation applied for 30 minutes at 370nm with 3mW/cm2). Corneal cross-linking is a routine procedure performed by Aravind Eye Hospital for infectious keratitis.
Study NCT02570321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti Fungal Drug
Description: Topical Amphotericin B vs Topical Natamycin
Study NCT02570321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti Fungal Drug
Description: Topical Amphotericin B vs Topical Natamycin
Study NCT04973488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange
Description: The intervention is a combination between the procedure of Therapeutic plasma exchange and biological transfusion of convalescent plasma from donors that have have COVID-19
Study NCT01103531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic and Resistance Exercise
Description: Aerobic and resistance exercise for 24 exercise training sessions over an 8-week period (three times weekly).
Study NCT01103531 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational information about health topics
Description: A counselor will meet with participants for 24 sessions (3 times/week) over an 8-week period to present and discuss information that includes topics on health and wellness, and lifestyle topics such as healthy eating, meditation, sleep hygiene, and cancer screening.
Study NCT00265811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folfox
Study NCT00265811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfox
Study NCT00265811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT00827892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Escalating doses for 3 days, then 30 mg orally daily for the duration of the study as determined by MRI
Study NCT00827892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Lactose Capsule administered by mouth daily for the duration of the study as determined by MRI
Study NCT02186964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tension free primary closure
Description: tension free primary closure of the defects created by excision of the pilonidal sinus
Study NCT02186964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: karydakis
Description: the defect after excision of the pilonidal sinus is closed by Karydakis procedure
Study NCT02186964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limberg flap
Description: defect after excision of the pilonidal sinus is closed by Limberg flap procedure
Study NCT01243385 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Metformin Lifelong follow-up at a target dose of 2 x 1000 mg daily Until progression, unacceptable toxicity or refusal
Study NCT02447991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rizatriptan
Description: During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of this study.
Study NCT02447991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of the study.
Study NCT04108039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRh antagonist
Description: In the antagonist cycle, LH suppression will be accomplished by subcutaneous (SC) injections of 0.25 mg of Cetrorelix or Ganirelix starting in the presence of follicles >14mm or E2 levels >400 pg/ml and continuing until ovulation triggering to avoid LH surge in COS